Chinese venture capital investment into US biotech companies in the first half has already surpassed the record set for the whole of last year, underlining Beijing’s focus on medicine as a strategic sector — a development that has flown under the radar of regulators in Washington.
今年上半年中國風險資本對美國生物技術公司的投資已經超出去年全年的創紀錄水準，突顯北京方面對醫藥作爲一個戰略行業的關注——這一動向迄今沒有受到華盛頓的監管者關注。
您已閱讀7%（361字），剩餘93%（4527字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。